{
  "meta": {
    "data_length": 1,
    "message": "Document id doc:fda:veppanu retrieved successfully",
    "request_url": "https://api.moalmanac.org/documents?document_id=doc%3Afda%3Aveppanu",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.002037,
    "timestamp_received": "2026-10-22T20:04:30.155221Z",
    "timestamp_returned": "2026-10-22T20:04:30.157258Z",
    "trace_id": "c2e375e6-7ef1-4d96-95d7-c58a1f511b10"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://moalmanac.org",
    "last_updated": "2026-10-08"
  },
  "data": [
    {
      "id": "doc:fda:veppanu",
      "type": "Document",
      "documentType": "Regulatory approval",
      "name": "Veppanu (vepdegestrant) [package insert]. FDA.",
      "title": null,
      "aliases": [],
      "description": "Rigel Pharms. Veppanu (vepdegestrant) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf. Revised May 2026. Accessed October 8, 2026.",
      "urls": [
        "https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf",
        "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219835"
      ],
      "doi": null,
      "pmid": null,
      "extensions": [
        {
          "name": "agent",
          "value": {
            "id": "agent:org:fda",
            "type": "Agent",
            "agentType": "organization",
            "name": "Food and Drug Administration",
            "description": "Regulatory agency that approves drugs for use in the United States."
          },
          "description": "The organization that published this document."
        },
        {
          "name": "company",
          "value": "Rigel Pharms",
          "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_brand",
          "value": "Veppanu",
          "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "drug_name_generic",
          "value": "vepdegestrant",
          "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
        },
        {
          "name": "first_publication_date",
          "value": "2026-05-01",
          "description": "The publication date for the initial version of this document."
        },
        {
          "name": "publication_date",
          "value": "2026-05-01",
          "description": "The publication date for the document."
        },
        {
          "name": "regulatory_identifier",
          "value": "NDA219835",
          "description": "Identifier assigned by the regulatory agency, such as an FDA application number (e.g. NDA208716, BLA125427) or an EMA product number (e.g. EMEA/H/C/006184)."
        },
        {
          "name": "status",
          "value": "Active",
          "description": "Whether this document is Active or Deprecated within moalmanac-db."
        }
      ]
    }
  ]
}